Moreover, TRAF2 was characterized as a low-risk gene in Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), and STAD (HR < 1, P < 0.05, Fig. 4, Table 2). This evidence concerns the gene TRAF2 and endocervical adenocarcinoma.